What is KeyCorp's Forecast for ALHC FY2027 Earnings?

Key Points

• KeyCorp forecasts that Alignment Healthcare will post an EPS of $0.37 for FY2027, with a current target price of $21.00 and an "Overweight" rating.
• Alignment Healthcare's stock has received varied ratings, with one analyst rating it a "Strong Buy," while six have issued a "Buy" rating and four a "Hold" rating, resulting in a consensus rating of "Moderate Buy."
• The company recently reported an earnings surprise with EPS of $0.07 for the last quarter, exceeding expectations of a negative EPS and showing a 49.0% revenue growth year-over-year.

Alignment Healthcare, Inc. (NASDAQ:ALHC - Free Report) - KeyCorp issued their FY2027 EPS estimates for Alignment Healthcare in a report released on Sunday, August 24th. KeyCorp analyst M. Gillmor forecasts that the company will post earnings of $0.37 per share for the year. KeyCorp currently has a "Overweight" rating and a $21.00 target price on the stock. The consensus estimate for Alignment Healthcare's current full-year earnings is ($0.69) per share.

Other research analysts have also issued reports about the stock. Stephens raised shares of Alignment Healthcare to a "strong-buy" rating in a research report on Monday, June 2nd. UBS Group boosted their price target on shares of Alignment Healthcare from $16.00 to $17.00 and gave the company a "neutral" rating in a research report on Friday, May 2nd. Wall Street Zen downgraded Alignment Healthcare from a "buy" rating to a "hold" rating in a research note on Sunday, August 10th. Zacks Research upgraded Alignment Healthcare to a "hold" rating in a research note on Friday, August 8th. Finally, Barclays upgraded Alignment Healthcare from an "underweight" rating to an "equal weight" rating and upped their target price for the stock from $9.00 to $13.00 in a research note on Thursday, July 31st. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have issued a Hold rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $18.83.

Alignment Healthcare Stock Down 1.6%

ALHC opened at $15.58 on Tuesday. The company has a debt-to-equity ratio of 2.29, a current ratio of 1.66 and a quick ratio of 1.66. The company's 50-day moving average is $13.79 and its 200 day moving average is $15.30. Alignment Healthcare has a fifty-two week low of $8.65 and a fifty-two week high of $21.06. The firm has a market capitalization of $3.09 billion, a P/E ratio of -55.64 and a beta of 1.16.

Alignment Healthcare (NASDAQ:ALHC - Get Free Report) last posted its earnings results on Wednesday, July 30th. The company reported $0.07 EPS for the quarter, topping the consensus estimate of ($0.07) by $0.14. The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $960.25 million. Alignment Healthcare had a negative net margin of 1.53% and a negative return on equity of 43.68%. The firm's revenue for the quarter was up 49.0% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.13) earnings per share. Alignment Healthcare has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS.

Institutional Investors Weigh In On Alignment Healthcare

Large investors have recently bought and sold shares of the business. MCF Advisors LLC grew its holdings in Alignment Healthcare by 87.6% during the first quarter. MCF Advisors LLC now owns 2,165 shares of the company's stock valued at $40,000 after purchasing an additional 1,011 shares during the period. Skandinaviska Enskilda Banken AB publ bought a new position in shares of Alignment Healthcare during the 1st quarter valued at about $42,000. SBI Securities Co. Ltd. increased its holdings in shares of Alignment Healthcare by 4,868.9% in the 2nd quarter. SBI Securities Co. Ltd. now owns 3,031 shares of the company's stock worth $42,000 after buying an additional 2,970 shares during the last quarter. KBC Group NV bought a new stake in shares of Alignment Healthcare in the 2nd quarter worth about $44,000. Finally, Amalgamated Bank increased its holdings in shares of Alignment Healthcare by 21.6% in the 1st quarter. Amalgamated Bank now owns 3,466 shares of the company's stock worth $65,000 after buying an additional 616 shares during the last quarter. 86.19% of the stock is currently owned by institutional investors.

Insider Activity

In other news, Director Joseph S. Konowiecki sold 25,000 shares of Alignment Healthcare stock in a transaction dated Thursday, July 31st. The shares were sold at an average price of $16.00, for a total transaction of $400,000.00. Following the sale, the director owned 1,152,049 shares of the company's stock, valued at approximately $18,432,784. The trade was a 2.12% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Hyong Kim sold 24,800 shares of the stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $16.00, for a total transaction of $396,800.00. Following the completion of the transaction, the insider owned 447,367 shares of the company's stock, valued at approximately $7,157,872. The trade was a 5.25% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 636,185 shares of company stock worth $9,235,468. 6.60% of the stock is owned by company insiders.

Alignment Healthcare Company Profile

Alignment Healthcare, Inc, a tech-enabled Medicare advantage company, operates consumer-centric health care platform for seniors in the United States. It provides customized health care designed to meet the needs of a diverse array of seniors through its Medicare advantage plans. The company was founded in 2013 and is based in Orange, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.